Does butyrate support intestinal barrier integrity and immune tolerance?

The short-chain fatty acid butyrate is a crucial mediator of gastrointestinal homeostasis, serving as both a vital metabolic substrate for colonocytes and a key signaling molecule governing mucosal physiology.

Epithelial barrier and immune tolerance mechanisms

• Barrier maintenance: At physiological levels (0.5 to 5 mM), butyrate directly strengthens the intestinal epithelial barrier. It activates AMP-activated protein kinase (AMPK), which drives the assembly and redistribution of key tight junction proteins, such as ZO-1 and occludin, to the cell membrane to increase transepithelial electrical resistance (TEER).
• Epigenetic regulation: Acting as a canonical histone deacetylase (HDAC) inhibitor, butyrate upregulates the transcription of sealing claudins (1, 3, and 4) and suppresses pore-forming claudin-2.
• Tolerogenic signaling: Butyrate promotes regulatory immune tolerance by inhibiting HDACs (including HDAC9) in CD4+ T cells. This increases histone H3 acetylation at the Foxp3 promoter and conserved non-coding sequences, stabilizing FOXP3+ regulatory T cell (Treg) differentiation. Furthermore, it activates GPR109A and GPR43 on dendritic cells, upregulating retinaldehyde dehydrogenase (RALDH1) and anti-inflammatory IL-10 production.

Mucosal surveillance under butyrate depletion

• Compensatory immune response: Secretory IgA (sIgA) serves as the frontline immunological barrier, neutralizing luminal antigens via immune exclusion. Elevated fecal sIgA is a well-established marker of active mucosal immune surveillance and defense activation.
• Barrier vulnerability: Depleted stool butyrate levels deprive colonocytes of energy and impair the AMPK/HDAC pathways necessary for tight junction integrity. This structural compromise increases paracellular permeability, allowing luminal antigens to translocate into the lamina propria.
• Heightened surveillance: The resulting antigen exposure triggers a compensatory, protective rise in fecal sIgA, reflecting a mucosal immune system operating on "high alert" to contain threats despite depleted metabolic and barrier support.

Bottom line

• Butyrate directly maintains the gut barrier and immune tolerance through AMPK activation and HDAC-mediated FOXP3+ Treg stabilization; a clinical pattern of low stool butyrate and elevated fecal sIgA reflects a compromised epithelial barrier undergoing compensatory mucosal immune activation.